Zacks Investment Research downgraded Atara Biotherapeutics Inc (NASDAQ:ATRA) to Sell in a report released today.
- Updated: September 22, 2016
Just yesterday Atara Biotherapeutics Inc (NASDAQ:ATRA) traded 0.54% higher at $20.06. Atara Biotherapeutics Inc’s 50-day moving average is $21.14 and its 200-day moving average is $20.02. The last closing price is up 2.19% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 112,523 shares of ATRA traded hands, down from an average trading volume of 201,888
Zacks Investment Research has downgraded Atara Biotherapeutics Inc (NASDAQ:ATRA) to Sell in a report released on 09/22/2016.
Recent Performance Chart
Atara Biotherapeutics Inc has one year low of $13.31 and a one year high of $45.80 and has a market capitalization of $0.
A total of 5 brokerages have issued a ratings update on the company. Three firms rating the stock a strong buy, one equity analyst rating the company a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 1 analyst rating the company a sell with a one year target of $28.60.
General Company Details For Atara Biotherapeutics Inc (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.